<DOC>
	<DOCNO>NCT00276055</DOCNO>
	<brief_summary>1.1 To determine recommended phase II dose gemcitabine combination fix dose docetaxel bevacizumab . 1.2 To determine efficacy combination gemcitabine , docetaxel , bevacizumab patient soft tissue sarcoma 1.3 To determine toxicity profile combination gemcitabine , docetaxel , bevacizumab patient soft tissue sarcoma</brief_summary>
	<brief_title>Phase IB Study Gemcitabine , Docetaxel Bevacizumab Patients With Soft Tissue Sarcoma</brief_title>
	<detailed_description>Because combination gemcitabine docetaxel show impressive activity soft tissue sarcoma , hypothesize addition antiangiogenesis agent ( bevacizumab ) would enhance anticancer activity , show tumor type .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Inclusion criterion : All patient , 18 year age old , chemotherapy naive soft tissue sarcoma eligible measurable disease Prior surgery radiotherapy primary tumor allow need complete least 2 week entry , patient completely recover procedure . Patients must life expectancy least 12 week . Patients must Zubrod performance status 02 . Patients must sign informed consent . Patients adequate bone marrow function define absolute peripheral granulocyte count &gt; 1,500 cells/mm3 platelet count &gt; 100,000/mm3 absence regular red blood cell transfusion requirement . Patients adequate hepatic function total bilirubin &lt; 2 mg/dl serum glutamate oxaloacetate transaminase ( SGOT ) serum glutamate pyruvate transaminase ( SGPT ) &lt; two time upper limit normal , adequate renal function define serum creatinine &lt; 1.5 x upper limit normal . Patients symptomatic brain metastasis exclude study . Pregnant woman nurse mother eligible trial . Patients child bear potential must use adequate contraception . Patients may receive concurrent chemotherapy radiation therapy trial . Patients severe medical problem uncontrolled diabetes mellitus cardiovascular disease active infection eligible trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Soft Tissue Sarcoma</keyword>
	<keyword>Phase I</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>vascular endothelial growth factor</keyword>
</DOC>